Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

This study sought to characterize images of cancer patients generated by Artificial Intelligence (AI) text-to-image tools, and assess whether images differed by cancer type or AI tool, to elucidate the potential implications of using AI-generated images in health communication. Two generative AI-based tools, and , were prompted to produce images of a "cancer patient," "breast cancer patient," "lung cancer patient," and "prostate cancer patient". Images ( = 320) were coded for perceived demographics, illness features, affect, cancer symbols, setting, and photorealism. Analysis revealed that AI tools commonly depicted cancer patients as White (83.2%) and middle-aged or older (87.5%). Compared to general cancer patient images, breast cancer patients were portrayed as younger, while prostate and lung cancer patients were depicted as older. Breast cancer patients were also more frequently depicted as healthy and displaying positive affect, while lung cancer patients were more often depicted as ill and showing negative affect. Differences were also found between the AI tools, with images featuring more racial diversity and being less photorealistic compared to images produced by . Because generative AI tools may produce images of cancer patients that are limited on some dimensions of diversity, and in some cases may reinforce stereotypes (eg, breast cancer patients as healthy and happy, lung cancer patients as ill and hopeless), it is critical to consider biases that may exist in these models - and the potential societal implications of using AI-generated images of cancer patients - before these tools are deployed in cancer communication efforts.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10410236.2025.2537807DOI Listing

Publication Analysis

Top Keywords

cancer patients
44
cancer
17
images cancer
12
cancer patient"
12
breast cancer
12
lung cancer
12
patients
11
images
11
images produced
8
produced generative
8

Similar Publications

Objective: The cachexia index (CXI) demonstrates potential as both a diagnostic tool for cachexia and a prognostic tool for survival in cancer. However, CXI's predictive value has not been verified in cervical cancer. The purpose of this study is to investigate the prognostic value of the CXI in patients with cervical cancer treated with radiotherapy.

View Article and Find Full Text PDF

Endothelial Colony-Forming Cells (ECFCs) are recognized as key vasculogenic progenitors in humans and serve as valuable liquid biopsies for diagnosing and studying vascular disorders. In a groundbreaking study, Anceschi et al. present a novel, integrative strategy that combines ECFCs loaded with gold nanorods (AuNRs) to enhance tumor radiosensitization through localized hyperthermia.

View Article and Find Full Text PDF

ASO Practice Guidelines Series: Soft Tissue Sarcoma of the Extremities and Superficial Trunk.

Ann Surg Oncol

September 2025

Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Soft tissue sarcomas (STS) are a heterogeneous group of rare malignant tumors arising from mesenchymal tissues, with extremity and superficial trunk STS (eSTS) comprising the majority of cases. The management of localized eSTS requires a multidisciplinary approach to optimize oncologic and functional outcomes. This review outlines the natural history, diagnostic workup, and treatment principles for localized eSTS, emphasizing the role of histology-specific considerations in guiding management strategies.

View Article and Find Full Text PDF

Purpose: Limited data is available assessing sequencing of antibody drug conjugates (ADCs) in patients with hormone receptor-positive (HR +), human epidermal growth factor 2 (HER2)-negative, HER2-low, and triple-negative metastatic breast cancer (MBC), including patients with brain metastases (BrM) or leptomeningeal disease (LMD). This study assesses the efficacy and safety of sequential sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) in MBC and impact on chemotherapy (CTX).

Methods: This is a single-center, retrospective, cohort study in adult patients with HR + , HER2-negative, or low MBC who received T-DXd and/or SG.

View Article and Find Full Text PDF